Adaptimmune Therapeutics PLC (ADAPY) stock: key figures, P/E, revenue and dividend

Health Care · United Kingdom

Price
0.03 USD
Market cap
7.42 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Adaptimmune Therapeutics PLC financials

Fiscal year2024
Revenue178.03 m USD
Gross profit177.96 m USD
Operating income-68.76 m USD
EBIT-63.89 m USD
Net income-70.81 m USD
Diluted EPS – continuing operations-0.05 USD

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.